2024
CONNEX, a Phase III Randomized Trial Program Assessing Efficacy and Safety of Iclepertin in Schizophrenia: Recruitment and Baseline Characteristics
Blahova Z, Ikezawa S, Falkai P, Krystal J, Rangan T. CONNEX, a Phase III Randomized Trial Program Assessing Efficacy and Safety of Iclepertin in Schizophrenia: Recruitment and Baseline Characteristics. BJPsych Open 2024, 10: s72-s73. PMCID: PMC11738127, DOI: 10.1192/bjo.2024.230.Peer-Reviewed Original ResearchVirtual Reality Functional Capacity Assessment ToolComposite T-scoreSchizophrenia Cognition Rating ScaleSchizophrenia Consensus Cognitive BatteryCognitive impairmentGlycine transporter-1 inhibitorStable antipsychotic treatmentN-methyl-d-aspartate receptor signallingConsensus Cognitive BatteryCognitive remediation therapyIncrease synaptic levelsCognition Rating ScaleT-scoreDuration of illnessCo-agonist glycineAntipsychotic treatmentAntipsychotic medicationSchizophrenia treatmentCognitive batteryRemediation therapyCognitive symptomsTreatment researchSchizophreniaImprove cognitionPlacebo-controlled parallel-group trial
2023
A feasibility study of the combination of intranasal insulin with oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk- Study rationale and design
Davidy T, Yore I, Cukierman-Yaffe T, Ravona-Springer R, Livny A, Lesman-Segev O, Azuri Y, Carmichael O, Kapogiannis D, Zetterberg H, Lin H, Sano M, Beeri M. A feasibility study of the combination of intranasal insulin with oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk- Study rationale and design. Mechanisms Of Ageing And Development 2023, 218: 111898. PMID: 38159613, DOI: 10.1016/j.mad.2023.111898.Peer-Reviewed Original ResearchConceptsMild cognitive impairmentIntranasal insulinCognitive benefitsCerebrovascular diseaseMetabolic syndromeIntent-to-treat sampleEfficacy of combination therapyPlacebo-controlled feasibility trialGLP-1 receptor agonistsOlder adultsCerebral glucose utilizationAdults aged >Cerebral blood flowNeurobiological markersOral semaglutideCombination therapyReceptor agonistsGlobal cognitionImprove cognitionSafety profileOlder adults aged >White matter hyperintensitiesSemaglutideCognitive impairmentGLP-1A feasibility study of the combination of intranasal insulin with dulaglutide for cognition in older adults with metabolic syndrome at high dementia risk – Study rationale and design
Davidy T, Yore I, Cukierman-Yaffe T, Ravona-Springer R, Livny A, Lesman-Segev O, Azuri Y, Carmichael O, Kapogiannis D, Zetterberg H, Lin H, Sano M, Beeri M. A feasibility study of the combination of intranasal insulin with dulaglutide for cognition in older adults with metabolic syndrome at high dementia risk – Study rationale and design. Mechanisms Of Ageing And Development 2023, 213: 111825. PMID: 37245533, PMCID: PMC12120971, DOI: 10.1016/j.mad.2023.111825.Peer-Reviewed Original ResearchConceptsMild cognitive impairmentIntranasal insulinCognitive benefitsIntent-to-treat sampleOlder adultsCerebrovascular diseaseMetabolic syndromeCerebral glucose utilizationEfficacy of combination therapyPlacebo-controlled feasibility trialNeurobiological markersGLP-1 receptor agonistsGlobal cognitionImprove cognitionDementia riskWhite matter hyperintensitiesCognitive impairmentAdults aged >Receptor agonistsCerebral blood flowCognitionCombination therapySafety profileOlder adults aged >Dulaglutide
2020
A double‐blind placebo‐controlled clinical trial testing the effect of hyperbaric oxygen therapy on brain and cognitive outcomes of mildly cognitively impaired elderly with type 2 diabetes: Study design
BenAri O, Efrati S, Hadanny A, Sano M, Bendlin B, Lin H, Liu X, Sela I, Almog G, Livny A, Sandler I, Ben‐Haim S, Sagi R, LeRoith D, Beeri M, Ravona‐Springer R. A double‐blind placebo‐controlled clinical trial testing the effect of hyperbaric oxygen therapy on brain and cognitive outcomes of mildly cognitively impaired elderly with type 2 diabetes: Study design. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2020, 6: e12008. PMID: 32296731, PMCID: PMC7153432, DOI: 10.1002/trc2.12008.Peer-Reviewed Original ResearchHyperbaric oxygen therapyCognitive outcomesEffect of hyperbaric oxygen therapyIntent-to-treat sampleEpisodic memory testsCerebral blood flowClinical trialsType 2 diabetesPrimary cognitive outcomeGlobal cognitive changeBrain glucose utilizationTraumatic brain injury patientsCerebral glucose utilizationOxygen therapyDouble-blind placebo-controlled clinical trialMild cognitive impairmentExecutive functionPlacebo-controlled clinical trialMemory testCognitive domainsNeurobiological outcomesCognitive changesCognitive improvementFluorodeoxyglucose positron emission tomographyImprove cognition
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply